Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

In Africa, cancer kills more people than HIV/AIDS, malaria and tuberculosis combined. Approximately 40 percent of cancer cases can be prevented and 40 percent can be cured with the right treatment. Together with Elekta, ministries of health in almost a dozen African nations are working to build up their radiation therapy infrastructures and save lives. [More]
Moderate exercise on a regular basis may improve cancer treatments

Moderate exercise on a regular basis may improve cancer treatments

Kansas State University kinesiology research offers encouraging information for cancer patients: A brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments. [More]
OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC). [More]
OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
Men who receive brachytherapy more likely to be cancer-free five years later

Men who receive brachytherapy more likely to be cancer-free five years later

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. [More]
Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival. [More]
Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain, on Sunday. [More]
Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

With the introduction of Elekta's new Leksell Gamma Knife Icon, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumor types and sizes. [More]
iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft Axxent Electronic Brachytherapy (eBx) System in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers. [More]
ViewRay to exhibit MRI-guided radiation therapy system at ESTRO Forum

ViewRay to exhibit MRI-guided radiation therapy system at ESTRO Forum

ViewRay, makers of the world's first and only MRI-guided radiation therapy system, announced today that the company will showcase its MRIdian System at the 3rd ESTRO Forum, the annual meeting of the European Society for Radiotherapy and Oncology, being held April 24-28, 2015 in Barcelona, Spain. [More]
Accuray to highlight CyberKnife, TomoTherapy technologies at ESTRO meeting

Accuray to highlight CyberKnife, TomoTherapy technologies at ESTRO meeting

Accuray Incorporated announced today that the company will highlight new CyberKnife and TomoTherapy technologies at the European Society for Therapeutic Radiology and Oncology meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. [More]
Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. [More]
Accuray's InCise MLC for CyberKnife M6 System now available outside the U.S.

Accuray's InCise MLC for CyberKnife M6 System now available outside the U.S.

Accuray Incorporated announced today that the InCise Multileaf Collimator (MLC) for the CyberKnife M6 System will now be available outside the United States in markets where it is approved for sale, in addition to the U.S. market where the InCise MLC was commercially launched in February 2015. [More]
Plaque can be used to predict, identify and treat diseases, say researchers

Plaque can be used to predict, identify and treat diseases, say researchers

Scraped from the gums, teeth and tongue in the form of plaque, the researchers behind Canada's first plaque bank are betting that the bacterial content of plaque will open up a new frontier of medicine. [More]
May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

The "Radiation and the Modern Management of Lymphoma" issue (May 1, 2015) of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology, is focused on the integral role of radiation therapy in current lymphoma treatment. [More]
UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

The radiation oncology team at UH Seidman Cancer Center at UH Geauga Medical Center performed the first-ever prostate cancer treatment on April 3 using a newly approved device. The device, called SpaceOAR System, enhances the efficacy of radiation treatment by protecting organs surrounding the prostate. The device, a temporary injectable gel, received FDA clearance on April 1. [More]
Genetically modified Salmonella can help kill cancer cells

Genetically modified Salmonella can help kill cancer cells

A new study has demonstrated that genetically modified Salmonella can be used to kill cancer cells. The study is published in this week's issue of mBio, an American Society for Microbiology online-only, open access journal. [More]
Elekta Healthcare Analytics to be introduced at HIMSS15

Elekta Healthcare Analytics to be introduced at HIMSS15

At the Healthcare Information and Management Systems Society's 2015 conference (HIMSS15), Elekta will introduce Elekta Healthcare Analytics, a solution for accelerating data analysis to improve clinical, operational and financial decision making. [More]
Researchers link loss of WAVE1 gene to lethal form of prostate cancer

Researchers link loss of WAVE1 gene to lethal form of prostate cancer

Researchers at Upstate Medical University and Harvard University have linked the loss of key gene, WAVE1, to a lethal form of prostate cancer, according to a study published in the journal Oncotarget. [More]
Two case studies provide potential new avenue for treatment of kidney cancer

Two case studies provide potential new avenue for treatment of kidney cancer

UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of kidney cancer. [More]
Advertisement
Advertisement